Top Story Today
A 7-2 Vote Just Brought the Cancer Blood Test One Giant Step Closer
An FDA advisory panel voted 7-2 that Grail's Galleri blood test, which screens for over 50 cancer types from a single blood draw, has benefits that outweigh its risks for adults 50 and older. Safety passed unanimously at 10-0. Specificity clocked in at 99.6%, meaning fewer than 4 in 1,000 healthy people would get a false alarm. The catch: no one has proven yet that Galleri actually saves lives. Grail expects a final FDA decision in early 2027, and if approved, the real battle shifts to insurance coverage.
Why it matters: If approved, Galleri would be the first multi-cancer screening blood test to reach the market, a shift from finding cancer organ by organ to scanning for dozens of types at once. That has the potential to reshape population-level cancer diagnostics entirely.
Read more →Clinical Wins and Regulatory Moves
Merck's Eye Drug Validates a Mechanism Nobody Had Proven Before
Merck's remigromig, a first-in-class Wnt-pathway drug, matched the standard of care in a pivotal diabetic macular edema trial. Instead of blocking leaky blood vessels like existing therapies, it tells retinal cells to repair themselves. The BRUNELLO Phase 2b/3 trial hit its primary endpoint at 52 weeks, opening a potential multi-billion-dollar opportunity in a market Regeneron has dominated for years.
Read more →Drug Number Seven Crashes IgA Nephropathy's Most Crowded Party
Roche and Ionis posted a Phase 3 win for sefaxersen in IgA nephropathy, a kidney disease that already has six approved treatments. The IMAgINATION trial showed significant proteinuria reduction at 37 weeks, but Roche declined to share the actual numbers. With monthly dosing via autoinjector, sefaxersen now enters one of biotech's most competitive races.
Read more →Kyverna's CAR-T Posts Clean One-Year Data While Rivals Hit Pause
Kyverna's miv-cel showed durable 12-month responses in stiff person syndrome and myasthenia gravis with zero high-grade toxicities. That matters because Novartis paused multiple autoimmune CAR-T trials after patient deaths and Bristol Myers also pulled back. A rolling FDA submission could make miv-cel the first approved therapy for SPS.
Read more →Trump's FDA Pick Faces a Senate Committee That Isn't Sold
Heidi Overton, Trump's nominee to lead the FDA, sat for her Senate confirmation hearing with no agency management experience and a committee chair publicly demanding "radical honesty" on vaccines. The math is tight: she likely needs every Republican vote to clear committee. Biotech is watching closely for signals on accelerated approvals and drug regulation.
Read more →Deals and Dollars
Roche Bets $2 Billion on a Startup Most People Haven't Heard Of
Roche signed a deal worth up to $2 billion with Atavistik Bio, a five-year-old Cambridge startup, for access to its discovery platform targeting allosteric protein sites. The $70 million upfront payment is modest, but the deal's scale for pre-clinical science signals how aggressively Big Pharma is hunting for what comes after GLP-1 drugs.
Read more →Lilly Wires $100M to Beijing While Washington Debates Cutting the Wire
Eli Lilly committed $100 million upfront to InnoCare Pharma, a Beijing-based biotech, in a deal worth up to $3.35 billion across five undisclosed targets. The partnership deepens Lilly's China strategy at a time when Congress is actively considering legislation to restrict cross-border biotech deals.
Read more →AI Drug Discoverer Enveda Raises $311M to Decode Plant Chemistry
Enveda Biosciences pulled in $311 million in Series E funding at a roughly $2 billion valuation, making it one of the year's biggest biotech venture rounds. The company uses AI to mine plant and microbial chemistry for drug candidates, with programs in human trials targeting eczema and inflammatory bowel disease.
Read more →Flagship Pioneering Lands a Pentagon Contract for Biodefense
The biotech venture firm behind Moderna just became a defense contractor. Flagship Pioneering secured a five-year, $47 million Department of War contract to develop countermeasures against biological threats, giving the Pentagon access to its ecosystem of 40+ companies. It's a signal that biotech is quietly being folded into national security infrastructure.
Read more →Policy and Big Picture
Nine Pharma CEOs Co-Sign a Rare SOS on Europe's Biotech Decline
Leaders from major pharma companies warned that Europe faces a worsening biotech decline. The continent's share of global clinical trials dropped from 22% to 12% in a decade while China surged past it. About 49% of new therapies never reach European patients at all.
Read more →Europe Finally Cracks Open the Door to Gene-Edited Crops
The EU passed its biggest agricultural biotech reform in two decades, creating a fast-track pathway for crops with small, targeted gene edits. A new two-tier system lets CRISPR-tweaked plants that mimic natural mutations skip the full GMO gauntlet. Bayer, Corteva, and BASF stand to benefit most as Europe's seed market opens up.
Read more →